On October 26, 2026, Realbotix announced the launch of its Echo humanoid robot platform, offering two models: the Echo Tabletop priced at $11,950 and the Echo Full Body priced at $59,950. The company plans an initial production run of 225 Tabletop units and 25 Full Body units, with deliveries expected in the second half of 2027. Echo robots are designed to enhance education, wellness, and social engagement through advanced AI enabling lifelike expressions, motion, vision, and social interaction. Manufactured in the United States, the robots incorporate patented AI and robotics technologies.
This announcement is shared in the context of Onconetix’s pending acquisition of Realbotix LLC, a wholly-owned subsidiary of Realbotix Corp. Onconetix, a biotechnology company focused on oncology solutions, entered into a definitive share exchange agreement to acquire Realbotix LLC in an all-stock transaction, subject to regulatory and shareholder approvals. The combined company is expected to trade on Nasdaq post-closing.
Realbotix’s Echo robot platform represents a significant advancement in humanoid robotics for enterprise and consumer applications.
Source: Yahoo Finance Singapore.